- Home
- QUIK vs NKTX Comparison
QUIK vs NKTX Comparison
Compare QUIK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- NKTX
- Stock Information
- Founded
- QUIK 1988
- NKTX 2015
- Country
- QUIK United States
- NKTX United States
- Employees
- QUIK N/A
- NKTX N/A
- Industry
- QUIK Semiconductors
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- QUIK Technology
- NKTX Health Care
- Exchange
- QUIK Nasdaq
- NKTX Nasdaq
- Market Cap
- QUIK 124.5M
- NKTX 147.7M
- IPO Year
- QUIK 1997
- NKTX 2020
- Fundamental
- Price
- QUIK $5.85
- NKTX $1.81
- Analyst Decision
- QUIK Strong Buy
- NKTX Strong Buy
- Analyst Count
- QUIK 3
- NKTX 5
- Target Price
- QUIK $10.87
- NKTX $13.25
- AVG Volume (30 Days)
- QUIK 210.9K
- NKTX 929.7K
- Earning Date
- QUIK 11-11-2025
- NKTX 11-10-2025
- Dividend Yield
- QUIK N/A
- NKTX N/A
- EPS Growth
- QUIK N/A
- NKTX N/A
- EPS
- QUIK N/A
- NKTX N/A
- Revenue
- QUIK $16,178,999.00
- NKTX N/A
- Revenue This Year
- QUIK N/A
- NKTX N/A
- Revenue Next Year
- QUIK $77.05
- NKTX N/A
- P/E Ratio
- QUIK N/A
- NKTX N/A
- Revenue Growth
- QUIK N/A
- NKTX N/A
- 52 Week Low
- QUIK $4.26
- NKTX $1.31
- 52 Week High
- QUIK $13.36
- NKTX $3.16
- Technical
- Relative Strength Index (RSI)
- QUIK 39.85
- NKTX 34.05
- Support Level
- QUIK $5.68
- NKTX $1.85
- Resistance Level
- QUIK $6.30
- NKTX $2.05
- Average True Range (ATR)
- QUIK 0.50
- NKTX 0.10
- MACD
- QUIK -0.20
- NKTX -0.03
- Stochastic Oscillator
- QUIK 8.86
- NKTX 3.75
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.